Mariam Alexander
@MariamAlex26
Followers
226
Following
2K
Statuses
102
Thoracic Med Onc @MUSChealth @muschollings Charleston, South Carolina. Former Heme/Onc fellow @MontefioreNYC @EinsteinMed
Joined June 2019
@BrunaPellini @MoffittNews @MoffittResearch @aadel_chaudhuri @JhanelleGray @HemOncWomenDocs @WomeninOnc @WomenInMedicine Love this article. You are awesome
1
0
2
0
1
4
RT @oncodaily: Advances in molecular targets for NSCLC - @NaglaAKarimMD
@MariamAlex26 @StephenVLiu @MUSChealth
0
3
0
RT @StephenVLiu: Fantastic multi-disciplinary panel to discuss early stage NSCLC at #DCLung24 with Drs. @SBroderickMD, @CharuAggarwalMD, Ma…
0
2
0
0
0
0
RT @StephenVLiu: Fantastic description of targeted therapy in the early stage lung cancer space from Dr. @MariamAlex26 at #DCLung24. Striki…
0
11
0
@StephenVLiu Thanks for the invitation @StephenVLiu it was an amazing experience learning from experts and loved connecting with old friends and making new ones! Awesome job putting it all together.
0
0
3
RT @NaglaAKarimMD: @MariamAlex26 presents all about before & after molecular targets in resectable NSCLC. Neoadjuvant Target Therapies aw…
0
4
0
0
0
1
@NaglaAKarimMD So lovely to see you always and to meet the amazing @triparnasen in person finally!
1
0
5
@DrSteveMartin @MontefioreNYC @EinsteinMed @MichaelSandhuMD So happy to see the Monte family. Thanks for getting us all together @DrSteveMartin
0
0
2
@DrSteveMartin Yes I agree especially for those of us not as used to managing CRS and ICANS all the time. And especially for our patients that live 3 hrs away which is all too common in my neck of the woods.
0
0
1
RT @StephenVLiu: FDA approves first perioperative immunotherapy regimen for resectable NSCLC. Based on KEYNOTE 671, #neoadjuvant pembrolizu…
0
53
0
RT @KateEEngelhardt: Good morning from Singapore! @muschollings representing at the #WCLC23 early career workshop 🤩🫁💪🏼
0
2
0
@KateEEngelhardt @WomenInThoracic @STS_CTsurgery @AATSHQ @ct_musc @muschollings @MUSCSurgery Well deserved! Congrats Kate
0
0
1
RT @StephenVLiu: Adjuvant alectinib significantly improves DFS for resected #ALK NSCLC! Phase III ALINA trial meets primary endpoint, per p…
0
50
0